Pfizer Inc
Pfizer Inc를 보는 글로벌 시선
이 종목 직접 발언을 우선한 글로벌 증권사·투자대가의 공개 원문 · RICHMAP 추천 아님
재무 요약
Finnhub /stock/metric · 연간 기준 · 캐시 6h▸ Finnhub /stock/profile2 · 캐시 24h · 모든 수치 API 원값 (RICHMAP 가공·추정 없음)
관련 뉴스
Finnhub /company-news · 최근 14일 · 캐시 30minAbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.
원문 보기 ↗ YahooWas JNJ Stock Rally Actually Its Own?
Johnson & Johnson (JNJ) stock returned 59.9% over the past year, against 21.1% for the S&P 500. The company has a clean story for it. The biosimilar hit it had been bracing for arrived and was absorbe…
원문 보기 ↗ YahooPfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?
Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in…
원문 보기 ↗ YahooAMGN's MariTide: Can Convenience Drive its Obesity Market Share?
Amgen's MariTide could target obesity with less frequent dosing, offering a convenience edge as competition from Lilly and Novo Nordisk intensifies.
원문 보기 ↗ YahooTrailing rivals, AbbVie scores win with dual-acting myeloma drug
The drugmaker is leaning on a better side effect profile compared to drugs from J&J, Pfizer and Regeneron as it pushes etentamig toward FDA submission.
원문 보기 ↗ YahooIonis’ rare neurology drug approved; Pfizer inks an ADC deal
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
원문 보기 ↗ YahooPfizer (PFE) Stock Looks Fully Valued As Earnings Run Ahead Of Value
Pfizer stock has quietly put up a 25.6% gain over the past year, yet broad valuation checks still do not flag it as either clearly cheap or clearly expensive. With mixed signals on value and fresh pro…
원문 보기 ↗ YahooPfizer (PFE) After FDA Vaccine Approval Faces A Fair Value Reality Check
Pfizer (PFE) has drawn fresh attention after the FDA approved its 2026 to 2027 COMIRNATY XFG COVID-19 vaccine formula for high risk age groups, adding a new chapter to the company’s vaccine story. Pfi…
원문 보기 ↗ YahooVaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Luis Jodar, Ph.D., Former Pfizer Chief Medical Officer for Vaccines and Infectious Diseases with Extensive Leadership Experience Across Clinical Development and Medical Affairs for Pneumococcal Conjug…
원문 보기 ↗ Yahoo3 Things You Need to Know If You Buy Pfizer Stock Today
After a long bout with poor post-pandemic performance, the stock's starting to perk up. The question is, are other investors -- and analysts -- willing to stick their neck out any further anytime soon…
원문 보기 ↗ YahooIs Merck Stock Pricing In A Post-Keytruda Future Too Soon?
Merck’s stock is the top performer in its group, but its profitability sits at the very bottom of the pack, forcing a hard question on investors.
원문 보기 ↗ YahooSummit Therapeutics Says It Is Beating Merck With Its Cancer Drug
Summit says its ivonescimab is keeping lung-cancer patients alive longer than Keytruda does. The stock is up.
원문 보기 ↗ Yahoo내 성향 트레이더로 도전
주어는 당신의 성향이지 이 종목이 아닙니다. 6시간부터 1년까지 운용기간을 고르면, AI가 기간에 맞는 주기로 가상 매매합니다. 페이지를 닫아도 서버에서 계속 진행됩니다.
트레이더 성향 설정
객관식만 · 주관식 0 · 생성 후 변경 불가
본 페이지는 정보 제공 목적의 종목 정보 색인이며, 투자 권유·자문·중개가 아닙니다. RICHMAP은 증권사·금융투자업자가 아닙니다. 시세·재무·뉴스는 외부 데이터 소스(Finnhub 등)의 정보로 실시간성·정확성을 보증하지 않습니다. 모든 수치는 API 원값으로 RICHMAP의 가공·추정이 없으며, 조회 실패 시 "데이터 없음"으로 명시됩니다. 투자 판단과 그 결과 책임은 본인에게 있으며, 실제 거래는 정식 인가 증권사를 통해 본인 판단하에 진행하시기 바랍니다.